This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Is There a Rally Ahead for Healthcare Stocks After Bristol Meyers Beat Earnings?

James Dennin, Kapitall: Bristol Meyers beat earnings estimates, but does that mean 2014 will be another good year for healthcare stocks?

Healthcare stocks and consumer goods giants like  Bristol Meyers Squibb (BMY) and Procter & Gamble (PG) are up today on the back of earnings reports that beat Wall Street's expectations. Bristol Meyers GAAP diluted EPS went up 21% for the quarter, sending shares up 3% during early morning trading, although the price has receded somewhat. 

Read more on Healthcare from Kapitall: Stock Watchlist for 2014: Biotechs, Medtechs and Pharmaceuticals

Procter & Gamble reported strong earnings as well, mostly on the back of rising sales on discretionary goods like diapers in emerging markets. Analysts estimated that earnings would be about $1.20 per share, which the company beat by a cent. As of 11:00 AM EST, the stock was up over 3%. 

Earnings reports have been highly scrutinized this January, as many on Wall Street worry about high valuations. All three of the major indices are down precipitously for the week, as investors adjust to an environment where choosing stocks is expected to be much trickier, and soaring prices are less common. 

Investing ideas

While Proctor & Gamble is primarily seen as a consumer goods maker, the largest in the world, the company also operates a healthcare segment. Based on the strong earnings of these two giants, we decided to build a list of healthcare stocks that are reporting earnings next week. 

Of the 30 or so healthcare stocks on that list, we narrowed it further based on  market cap, profit margins, and projected EPS growth. 

Small and micro-cap healthcare stocks are very risky, since their price often hinges on FDA approval for a particular product. So we only included companies with a market cap above $2 billion. All of these companies also have fairly high profit margins, above 10%.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs